Trial Profile
Phase II study of interleukin-2 in combination with zoledronic acid in patients with untreated metastatic renal cell carcinoma.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Interleukin-2 (Primary) ; Zoledronic acid (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- 26 Mar 2010 Actual patient number (12) added as reported by ClinicalTrials.gov.
- 26 Mar 2010 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 21 Jan 2008 New trial record.